Richard Daniell became Executive Vice President, European Commercial in November 2017, leading all activities of Teva Europe’s Generic, Specialty and over the counter (OTC) businesses as well as our Teva API and Medis B2B units.

With headquarters in The Netherlands, Teva Europe employs approximately 19,000 people in the region and covers 36 countries. Teva is Europe’s biggest provider of tried-and-trusted generic medicine, a leading provider of OTC medicines and a recognized innovator in CNS, respiratory medicines and biopharmaceuticals.

Before assuming this responsibility, Richard headed up Teva Europe Generics. Prior to that he served as Chief Operating Officer of International Markets and led the integration of the Actavis Generics business into Teva globally. Before that he served as General Manager for the United Kingdom and Ireland.

Richard received his B.Sc. degree in chemistry from the University of Auckland, New Zealand.